{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:34:01Z","timestamp":1789569241576,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic antibiotic-refractory pouchitis (CARP) is a complex and often debilitating complication following ileal pouch-anal anastomosis (IPAA). Vedolizumab (VDZ), a gut-selective anti-integrin agent, has shown potential efficacy in this context, but real-world evidence remains limited. This study aimed to evaluate the effectiveness, safety, and treatment persistence of VDZ in patients with CARP, including outcomes after transitioning from intravenous (IV) to subcutaneous (SC) administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter Spanish study (POUCHIVED) included patients with CARP treated with VDZ. Disease activity was assessed using the modified Pouchitis Disease Activity Index (mPDAI). mPDAI, fecal calprotectin (FC), C-reactive protein (CRP), and serum VDZ levels were recorded at weeks 12, 24, and 52 during IV treatment, and subsequently after switching to SC administration when applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-seven patients (66% male; median age 51 years) were included, of whom 53% transitioned to SC VDZ. Most patients presented mild pouchitis at baseline, reflecting early initiation of vedolizumab in clinical practice. IV VDZ therapy led to significant reductions in mPDAI and FC at all evaluated time points: mPDAI decreased from a baseline median of 5 [IQR 3\u20137] to 3 [2\u20135], 2 [2\u20135], and 2 [2\u20135.8] at weeks 12, 24, and 52, respectively (p&amp;lt;0.05) and FC declined from 443\u00a0\u00b5g\/g [IQR 213\u2013746] at baseline to 329 \u00b5g\/g [145\u2013701], 193 \u00b5g\/g [91\u2013412], and 178 \u00b5g\/g [101\u2013640] at the same intervals. Following the switch to SC VDZ, both mPDAI and FC showed further improvement at week 52, while CRP levels remained unchanged. SC VDZ was associated with higher serum drug concentrations compared to IV. Better clinical outcomes were observed in patients with fewer prior therapies post-surgery, while baseline corticosteroid or immunosuppressant use and prior VDZ exposure before IPAA did not influence response. Treatment persistence was high, and adverse event rates were comparable between IV and SC formulations (8.5%\n                      <jats:italic>vs<\/jats:italic>\n                      . 12%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>VDZ is effective and safe for the management of CARP, particularly when used at first line in the treatment course. Transitioning from IV to SC administration maintains clinical remission and is well tolerated in real-world clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1630678","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:44:46Z","timestamp":1765953886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study)"],"prefix":"10.3389","volume":"16","author":[{"given":"Leticia","family":"Gimeno-Pitarch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"C\u00e9spedes-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Ferreiro-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Mart\u00edn-Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Sicilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inma","family":"Lorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mesonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Vicente-Lid\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"M\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Galvez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Serra-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro-de Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Iborra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrgastro.2012.58","article-title":"Acute and chronic pouchitis - Pathogenesis, diagnosis and treatment","volume":"9","author":"Shen","year":"2012","journal-title":"In Nat Rev Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz227","article-title":"Inflammatory pouch conditions are common after ileal pouch anal anastomosis in ulcerative colitis patients","volume":"26","author":"Kayal","year":"2020","journal-title":"Inflammatory Bowel Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goz001","article-title":"Vedolizumab for chronic antibiotic-refractory pouchitis","volume":"7","author":"Singh","year":"2019","journal-title":"Gastroenterol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100095","article-title":"Medical management of chronic pouch inflammation","volume":"3","author":"Kayal","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2024.09.023","article-title":"Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU","volume":"57","author":"Mesonero","year":"2025","journal-title":"Digestive Liver Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/175628482412344766","article-title":"Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU","volume":"17","author":"Mesonero","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081870","article-title":"Long-term outcomes of first-line anti-TNF therapy for chronic inflammatory pouch conditions: A multi-centre multi-national study","volume":"13","author":"Ghersin","year":"2025","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/S2468-1253(21)00214-4","article-title":"Treatment of pouchitis, Crohn\u2019s disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium","volume":"7","author":"Shen","year":"2002","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90832-x","article-title":"Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment","volume":"107","author":"Sandborn","year":"1994","journal-title":"Gastroenterology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","article-title":"AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders","volume":"166","author":"Barnes","year":"2024","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14479","article-title":"Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis","volume":"47","author":"B\u00e4r","year":"2018","journal-title":"Alimentary Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"New Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S341","DOI":"10.1093\/ecco-jcc\/jjy222.583","article-title":"P459 Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience","volume":"13","author":"Cesano","year":"","journal-title":"J Crohns Colitis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz030","article-title":"Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a multicenter US cohort","volume":"25","author":"Gregory","year":"2019","journal-title":"Inflammatory Bowel Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cgh.2016.05.012","article-title":"Negative effects on psychological health and quality of life of genuine irritable bowel syndrome\u2013type symptoms in patients with inflammatory bowel disease","volume":"15","author":"Gracie","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.04.015","article-title":"Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study","volume":"21","author":"Barnes","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastre.2025.502201","article-title":"Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease","volume":"48","author":"Amor Costa","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2025.502379","article-title":"High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study","volume":"48","author":"Andr\u00e9s","year":"2025","journal-title":"Gastroenterologia y Hepatologia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2176252","article-title":"Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring","volume":"58","author":"Wiken","year":"2023","journal-title":"Scandinavian J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020239","article-title":"Real-world study on vedolizumab serum concentration, efficacy, and safety after the transition from intravenous to subcutaneous vedolizumab in inflammatory bowel disease patients: single-center experience","volume":"16","author":"Or\u0161i\u0107 Fri\u010d","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx049","article-title":"Systematic review with meta-analysis: anti-TNF therapy in refractory pouchitis and crohn\u2019s disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis","volume":"24","author":"Huguet","year":"2018","journal-title":"Inflammatory Bowel Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001550","article-title":"Safety and efficacy of biological therapy in chronic antibiotic refractory pouchitis: A systematic review with meta-analysis","volume":"55","author":"Saurabh","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001467","article-title":"Exposure to anti-tumor necrosis factor medications increases the incidence of pouchitis after restorative proctocolectomy in patients with ulcerative colitis","volume":"62","author":"Zoccali","year":"2019","journal-title":"Dis Colon Rectum"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.cgh.2020.07.008","article-title":"Recycling of precolectomy anti-tumor necrosis factor agents in chronic pouch inflammation is associated with treatment failure","volume":"19","author":"Kayal","year":"2021","journal-title":"In Clin Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02938-6","article-title":"Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis","volume":"23","author":"Chu","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"In Clin Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/S2468-1253(24)00317-0.27","article-title":"Vedolizumab to prevent postoperative recurrence of Crohn\u2019s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"Geert D\u2019Haens","year":"2025","journal-title":"In Lancet Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab053","article-title":"Vedolizumab tissue concentration correlates to mucosal inflammation and objective treatment response in inflammatory bowel disease","volume":"27","author":"Pauwels","year":"2021","journal-title":"Inflammatory Bowel Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115817","article-title":"Colonic epithelial permeability to ions is restored after vedolizumab treatment and may predict clinical response in inflammatory bowel disease patients","volume":"25","author":"Cicala","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47618-3","article-title":"Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis","volume":"13","author":"Miyazaki","year":"2023","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6(4)","DOI":"10.1093\/crocol\/otae061","article-title":"Real-world treatment outcomes associated with early versus delayed vedolizumab initiation in patients with ulcerative colitis","volume":"360","author":"Cleveland","year":"2024","journal-title":"Crohn\u2019s Colitis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317977","article-title":"Immune cell trafficking and retention in inflammatory bowel disease: Mechanistic insights and therapeutic advances","volume":"68","author":"Zundler","year":"2019","journal-title":"In Gut"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.014","article-title":"Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives","volume":"162","author":"Irving","year":"2022","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"In Am J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz041","article-title":"Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease","volume":"13","author":"Ungaro","year":"2019","journal-title":"J Crohn\u2019s Colitis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab224","article-title":"Transitioning from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease [TRAVELESS","volume":"16","author":"Ventress","year":"2022","journal-title":"J Crohn\u2019s Colitis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16927","article-title":"Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease","volume":"55","author":"Bergqvist","year":"2022","journal-title":"Alimentary Pharmacol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619871797","article-title":"Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience","volume":"7","author":"Verstockt","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000593","article-title":"Incidence and severity of prepouch ileitis: A distinct disease entity or a manifestation of refractory pouchitis","volume":"22","author":"Samaan","year":"2016","journal-title":"Inflammatory Bowel Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e70252","DOI":"10.1111\/codi.70252","article-title":"Long-term outcomes of biologic therapy for the treatment of prepouch ileitis: A multi-centre multi-national retrospective study","volume":"27","author":"Ghersin","year":"2025","journal-title":"Colorectal Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:44:48Z","timestamp":1765953888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1630678"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1630678","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1630678"}}